(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.14%) $83.50
(-0.24%) $2.47
(0.13%) $2 342.00
(0.41%) $29.74
(0.39%) $992.60
(0.05%) $0.931
(0.15%) $10.66
(0.05%) $0.791
(-0.01%) $86.75
Live Chart Being Loaded With Signals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...
Stats | |
---|---|
Today's Volume | 272 198 |
Average Volume | 270 556 |
Market Cap | 527.92M |
EPS | $-0.830 ( Q1 | 2024-05-07 ) |
Next earnings date | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-7.16 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.170 (0.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Moran Sean F. | Buy | 7 788 | Common Stock, par value $0.0001 per share |
2024-06-17 | Moran Sean F. | Buy | 6 730 | Common Stock, par value $0.0001 per share |
2024-06-18 | Moran Sean F. | Buy | 1 958 | Common Stock, par value $0.0001 per share |
2024-06-14 | Moran Sean F. | Buy | 1 567 | Common Stock, par value $0.0001 per share |
2024-06-14 | Moran Sean F. | Sell | 7 788 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
93.13 |
Last 97 transactions |
Buy: 7 365 367 | Sell: 125 718 |
Volume Correlation
Corbus Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
OZEM | 1 |
NTNX | 0.945 |
SMH | 0.943 |
NVDA | 0.938 |
AMAT | 0.937 |
WING | 0.935 |
KBWP | 0.935 |
NVMI | 0.933 |
KLAC | 0.931 |
BUFF | 0.929 |
10 Most Negative Correlations | |
---|---|
ACON | -0.951 |
ARBB | -0.949 |
AGFY | -0.939 |
AGRI | -0.935 |
CHUY | -0.932 |
FATBW | -0.93 |
FWRD | -0.928 |
GMBL | -0.922 |
TBLT | -0.92 |
WBD | -0.917 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Corbus Pharmaceuticals Correlation - Currency/Commodity
Corbus Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-641 000 (0.00 %) |
EPS: | $-10.31 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-641 000 (0.00 %) |
EPS: | $-10.31 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-1.49M (0.00 %) |
EPS: | $-13.39 |
FY | 2021 |
Revenue: | $881 705 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators